Dystrophin as a biochemical outcome measure in Duchenne muscular dystrophy clinical trials

被引：0
|
作者：
Sardone, V. [1 ]
Ellis, M. [2 ]
Torelli, S. [1 ]
Feng, L. [1 ]
Chambers, D. [1 ]
Ricotti, V. [1 ]
Domingos, J. Pisco [1 ]
Phadke, R. [1 ,3 ]
Sewry, C. A. [3 ]
Morgan, J. [1 ]
Muntoni, F. [1 ]
机构：
[1] UCL Inst Child Hlth, Dubowitz Neuromuscular Ctr, London, England
[2] UCL Inst Neurol, Dept Neurodegenerat Dis, London, England
[3] Great Ormond St Hosp Sick Children, London, England
来源：
NEUROMUSCULAR DISORDERS | 2016年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P41
引用
收藏
页码：S16 / S16
页数：1
相关论文
共 50 条
  • [1] Revertant fibres and dystrophin traces in Duchenne muscular dystrophy: Implication for clinical trials
    Arechavala-Gomeza, Virginia
    Kinali, Maria
    Feng, Lucy
    Guglieri, Michela
    Edge, Geraldine
    Main, Marion
    Hunt, David
    Lehovsky, Jan
    Straub, Volker
    Bushby, Kate
    Sewry, Caroline A.
    Morgan, Jennifer E.
    Muntoni, Francesco
    NEUROMUSCULAR DISORDERS, 2010, 20 (05) : 295 - 301
  • [2] Novel image analysis to assess molecular functionality of dystrophin in Duchenne muscular dystrophy clinical trials
    Scaglioni, D.
    Catapano, F.
    Ellis, M.
    Torelli, S.
    Chambers, D.
    Feng, L.
    Husayni, S.
    Malhotra, J.
    Harriman, S.
    Koenig, E.
    Dugar, A.
    Steiner, D.
    Morgan, J.
    Phadke, R.
    Muntoni, F.
    NEUROMUSCULAR DISORDERS, 2020, 30 : S82 - S82
  • [3] OUTCOME MEASURES FOR DUCHENNE MUSCULAR DYSTROPHY: IMPLICATIONS FOR TRIALS
    Domingos, Joana
    Eagle, Michelle
    Moraux, Amelie
    Butler, Jordan
    Decostre, Valerie
    Ridout, Deborah
    Mayhew, Anna
    Selby, Victoria
    Guglieri, Michela
    Van der Holst, Menno
    Jansen, Merel
    Verschuuren, Jan G. M.
    de Groot, Imelda
    Niks, Erik
    Servais, Laurent
    Hogrel, Jean-Yves
    Straub, Volker
    Voit, Thomas
    Ricotti, Valeria
    Muntoni, Francesco
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2017, 88 : A63 - A63
  • [4] Reliable surrogate outcome measures in multicenter clinical trials of duchenne muscular dystrophy
    Mayhew, Jill E.
    Florence, Julaine M.
    Mayhew, Thomas P.
    Henricson, Erik K.
    Leshner, Robert T.
    McCarter, Robert J.
    Escolar, Diana M.
    MUSCLE & NERVE, 2007, 35 (01) : 36 - 42
  • [5] DYSTROPHIN DEFICIENCY IN DUCHENNE MUSCULAR-DYSTROPHY
    ISHIURA, S
    ARAHATA, K
    TSUKAHARA, T
    SUGITA, H
    SEIKAGAKU, 1989, 61 (11): : 1371 - 1375
  • [6] Biomarker panel for Duchenne muscular dystrophy clinical trials
    Tsioutsias, I.
    Bautista, A.
    Terrill, J.
    Bakker, A.
    Pinniger, G.
    Arthur, P.
    NEUROMUSCULAR DISORDERS, 2024, 43
  • [7] Duchenne muscular dystrophy: clinical trials and emerging tribulations
    Shieh, Perry B.
    CURRENT OPINION IN NEUROLOGY, 2015, 28 (05) : 542 - 546
  • [8] Cumulative jerk as an outcome measure in nonambulatory Duchenne muscular dystrophy
    Fujii, Tatsuya
    Takeshita, Eri
    Iwata, Yasuyuki
    Yajima, Hiroyuki
    Nozaki, Fumihito
    Mori, Mioko
    Kumada, Tomohiro
    BRAIN & DEVELOPMENT, 2019, 41 (09): : 796 - 802
  • [9] Clinical trials of exon skipping in Duchenne muscular dystrophy
    Mendell, Jerry R.
    Sahenk, Zarife
    Rodino-Klapac, Louise R.
    EXPERT OPINION ON ORPHAN DRUGS, 2017, 5 (09): : 683 - 690
  • [10] Outcome measures in Duchenne muscular dystrophy: sensitivity to change, clinical meaningfulness, and implications for clinical trials
    Domingos, Joana
    Muntoni, Francesco
    DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY, 2018, 60 (02): : 117 - 117
12345